Eli Lilly and Company (LLY)
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off has been unwarranted indeed, since the lowered FY2024 guidance is attributed to the complexities of inventory management and non-cash/ one-time IPR&D charges. Even so, the pullback has been a gift for opportunistic investors, with the stock now trading nearer to our recommended buy zones. If anything, LLY is even cheaper at FWD PEG non-GAAP ratio of 0.85x, well below historical trends and its direct peer.
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (LLY -0.26%) has lost some momentum; the company's shares are down by 11% since June 1. However, the healthcare leader still has plenty of fans on Wall Street, including Israel Englander, the billionaire owner of Millennium Management, a hedge fund.
2 Incredible Growth Stocks to Buy With $1,000 Right Now
2 Incredible Growth Stocks to Buy With $1,000 Right Now
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Eli Lilly and Co. LLY has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month.
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
Eli Lilly's cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.
Lilly pill cuts genetic form of cholesterol nearly 86% in study
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on Monday.
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
